Our results suggest that there may indeed be hyperactivation of AMPK in a sample of non-FXTAS PM carriers compared with the activities of this enzyme in normal controls and carriers affected with FXTAS. The gene discussed is PRKAA1; the disease is fragile X-associated tremor/ataxia syndrome.